Drug-drug interactions between letermovir and targeted therapies for graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: How do drug-drug interaction checkers compare?

Resources

Everything you might need. In one page.

Drug-drug interactions between letermovir and targeted therapies for graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: How do drug-drug interaction checkers compare?

Global DDI Solutions

The ASCPT Annual Meeting, the largest clinical pharmacology conference in the U.S., was held at the end of May. The event brought together a diverse audience: approximately 70% from the pharmaceutical industry, 20% academic researchers, and 10% regulators.

David Burger presented two posters on DDI management in prostate cancer and CMV. The study on CMV showed inconsistencies for letermovir with GVHD therapies, emphasizing the need for harmonized, evidence-based DDI guidance.

Find the poster on DDI management in prostate cancer here